Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib effectively regrows hair in severe alopecia areata cases.

Dupilumab may cause hair loss, so patients should be monitored.

Baricitinib is effective and safe for treating severe alopecia areata.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Alopecia areata greatly harms quality of life, causing emotional and social issues.

Baricitinib is effective and safe for treating severe alopecia areata.

People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.

Kids with alopecia areata may experience more stress but not necessarily feel more anxious or depressed than others.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

People with alopecia areata often have lower vitamin D levels, which are linked to more severe and longer-lasting hair loss, but vitamin D receptor levels in the skin don't show the same pattern and don't predict treatment success.

People with alopecia areata often have higher rates of allergies and autoimmune diseases.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.

Regenerative therapies show promise for treating vitiligo and alopecia areata.

Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.

Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.

The hepatitis B vaccine did not cause hair loss in the tested mice.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.